ProPhase Labs Q1 2024 GAAP EPS $(0.07) Beats $(0.18) Estimate, Sales $3.634M Miss $9.860M Estimate

5/9/24 8:02:27 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $PRPH alert in real time by email

ProPhase Labs (NASDAQ:PRPH) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.18) by 61.11 percent. The company reported quarterly sales of $3.634 million which missed the analyst consensus estimate of $9.860 million by 63.14 percent. This is a 81.17 percent decrease over sales of $19.303 million the same period last year.

Get the next $PRPH alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$PRPH

Date	Price Target	Rating	Analyst
1/14/2022	$12.00 → $15.00	Buy	HC Wainwright & Co.
12/20/2021	$12.00	Buy	HC Wainwright & Co.
10/13/2021		Buy → Neutral	Dawson James

More analyst ratings

$PRPH
Leadership Updates

Live Leadership Updates

ProPhase Labs Unveils Project ZenQ-AI
Leveraging ProPhase Labs' AI platform, massive genomics database and patented esophageal cancer insights for Antibody Drug Conjugates development. Garden City, NY, April 16, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH) ("ProPhase" or the "Company"), a biopharma, genomics, and diagnostics Company, today announced an innovative step forward in cancer treatment research with the introduction of Project ZenQ-AI. This project employs the Company's state-of-the-art AI platform which was meticulously developed with leading AI technology platforms and systems. The Company is harnessing its extensive genomic database—built over the last six years from whole genome sequencing tests (W
4/16/24 8:00:00 AM ET
$PRPH
Biotechnology: Pharmaceutical Preparations
Health Care
Sidus Space Appoints Bill White as Chief Financial Officer
Sidus Space (NASDAQ:SIDU) (the "Company" or "Sidus"), a multi-faceted Space and Data-as-a-Service company, today announced the appointment of Bill White as Chief Financial Officer, effective February 20, 2024. Mr. White will oversee the Company's accounting, financial planning, capital raise, treasury, legal and regulatory functions. Mr. White has more than 30 years of experience in financial management, operations, and business development. He most recently served as Chief Financial Officer of ProPhase Labs, Inc. (NASDAQ:PRPH) and prior to ProPhase he was CFO, treasurer, and secretary of Intellicheck, Inc., a technology company listed on the NasdaqGM. Mr. White has broad domestic and int
2/8/24 8:30:00 AM ET
$PRPH
$SIDU
Biotechnology: Pharmaceutical Preparations
Health Care
Telecommunications Equipment
Telecommunications
Nebula Genomics Strengthens Advisory Board with Appointment of Russ Altman, M.D., Ph.D.
GARDEN CITY, NY, Oct. 17, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH), a growth-oriented and diversified diagnostics, genomics and biotech company, today announced that its wholly owned subsidiary, Nebula Genomics, Inc., has added Russ B. Altman, M.D., Ph.D to its Advisory Board. Dr. Altman is the Kenneth Fong Professor of Bioengineering, Genetics, Medicine, Biomedical Data Science and Computer Science, and past chair of the Bioengineering Department at Stanford University. Dr. Altman is the second member of Nebula's Advisory Board and joins Dr. George Church, Nebula's Founder and Advisory Board Chairman. Nebula Genomics, a global leader in direct-to-consumer whole genome se
10/17/22 8:00:00 AM ET
$PRPH
Biotechnology: Pharmaceutical Preparations
Health Care

ProPhase Labs Announces Financial Results for the Three Months Ended September 30, 2024
Highlights Q4 2024 and Q1 2025 with multiple potential liquidity events, growth in multiple subsidiaries as well as potentially significant reduction in overhead and expenses Company to hold a virtual conference call Wednesday, November 13, 2024, at 11:00 AM ET GARDEN CITY, NY, Nov. 13, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH) ("ProPhase" or the "Company"), a next-generation biotech, genomics, and diagnostics company, today reported its financial and operational results for the three months ended September 30, 2024. The Company also highlighted substantial progress in its ongoing strategic initiatives, which are expected to drive significant revenue growth a
11/13/24 8:00:00 AM ET
$PRPH
Biotechnology: Pharmaceutical Preparations
Health Care
ProPhase Labs Inc. to Present Third Quarter 2024 Financial Results on November 13, 2024
GARDEN CITY, NY, Nov. 11, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ:PRPH), (the "Company" or "ProPhase"), a next generation biotech, genomics and diagnostics company, today announced that they will be presenting third quarter 2024 financial results on a virtual conference call hosted by Renmark Financial on November 13, 2024 at 11:00 AM EST. A press release detailing these results will be issued prior to the virtual conference call. ProPhase Labs Inc. welcomes stakeholders, investors, and other individual followers to register and attend this live event. Investors interested in participating in this live event will need to register using the link below. After the event, a replay
11/11/24 9:52:00 AM ET
$PRPH
Biotechnology: Pharmaceutical Preparations
Health Care
ProPhase Labs Announces Financial Results for the Three Months Ended June 30, 2024
Company Anticipates Significant Sequential Growth in Quarterly Revenues Beginning in Q3 2024 and Beyond Reports Pharmaloz Growth Acceleration Has Begun in Q3 2024 and Potential Sale of Business Announces Major DTC Initiatives for Nebula Genomics, anticipating new sales ramp in Q4 2024 Company to hold a virtual conference call Wednesday, August 14, 2024, at 11:00 AM ET GARDEN CITY, NY, Aug. 14, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH) ("ProPhase" or the "Company"), a next-generation biotech, genomics, and diagnostics company, today reported its financial and operational results for the three months ended June 30, 2024. The Company also highlighted subs
8/14/24 8:00:00 AM ET
$PRPH
Biotechnology: Pharmaceutical Preparations
Health Care

Impact BioMedical Inc. Issues Shareholder Letter Highlighting Recent Achievements and Strategic Vision
HOUSTON, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE:IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare solutions, today announced that Frank D. Heuszel, Chairman and Chief Executive Officer of Impact BioMedical Inc., issued the following letter to Impact BioMedical shareholders regarding recent achievements, executional efficiencies and the positive outlook for the Company's future. Dear Impact Biomedical Inc. (IBO) Shareholders, We closed our first quarter as a publicly traded company and wanted to address all current and future stakeholders highlighting our recent achievements, our appreciation for your
11/19/24 8:00:00 AM ET
$IBO
$PRPH
Biotechnology: Pharmaceutical Preparations
Health Care
Diamond Equity Research Releases Update Note on ProPhase Labs Inc. (NASDAQ: PRPH)
New York, NY, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Diamond Equity Research, an equity research firm with a focus on small capitalization public companies has released an Update Note on ProPhase Labs Inc. (NASDAQ:PRPH). The update note includes information on ProPhase's business model, services offered, industry outlook, financial results, management commentary, valuation, and risks. The update note is available below. ProPhase Labs November 2024 Update Note Highlights from the note include: Launch of Direct-to-Consumer DNA Complete and DNA Expand Genetic Testing Offerings: In Q3 FY2024, ProPhase Labs launched two significant product offerings, DNA Complete and DNA Expand, under it
11/18/24 8:00:00 AM ET
$PRPH
Biotechnology: Pharmaceutical Preparations
Health Care
ProPhase Labs Announces Financial Results for the Three Months Ended September 30, 2024
Highlights Q4 2024 and Q1 2025 with multiple potential liquidity events, growth in multiple subsidiaries as well as potentially significant reduction in overhead and expenses Company to hold a virtual conference call Wednesday, November 13, 2024, at 11:00 AM ET GARDEN CITY, NY, Nov. 13, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH) ("ProPhase" or the "Company"), a next-generation biotech, genomics, and diagnostics company, today reported its financial and operational results for the three months ended September 30, 2024. The Company also highlighted substantial progress in its ongoing strategic initiatives, which are expected to drive significant revenue growth a
11/13/24 8:00:00 AM ET
$PRPH
Biotechnology: Pharmaceutical Preparations
Health Care

$PRPH
Market Insights

Live Market Insights

ProPhase Labs Announces Update On Pharmaloz Manufacturing Progress; Says PMI's 12-Month Forward Looking Revenue Run Rate With One Production Line Will Be ~$14M-16M And ~$5M In Pre-Tax Net Profits
PMI Revenues and Earnings Projected to Grow Significantly in the Second Half of 2024 and Full Year 2025. New Strategic Initiatives for PMI Create Significant Opportunities for Liquidity and Value CreationGarden City, NY, July 11, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH) ("ProPhase" or the "Company"), a next-generation biotech, genomics, and diagnostics company, today reported that Pharmaloz Manufacturing, Inc. ("PMI"), its wholly-owned subsidiary, is projecting significant revenues and earnings growth for the second half of 2024 and the entire year of 2025. The Company believes that the strategic enhancements to PMI's primary production line have generated increased capacit
7/11/24 8:12:08 AM ET
$PRPH
Biotechnology: Pharmaceutical Preparations
Health Care
ProPhase Labs Q1 2024 GAAP EPS $(0.07) Beats $(0.18) Estimate, Sales $3.634M Miss $9.860M Estimate
ProPhase Labs (NASDAQ:PRPH) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.18) by 61.11 percent. The company reported quarterly sales of $3.634 million which missed the analyst consensus estimate of $9.860 million by 63.14 percent. This is a 81.17 percent decrease over sales of $19.303 million the same period last year.
5/9/24 8:02:27 AM ET
$PRPH
Biotechnology: Pharmaceutical Preparations
Health Care
ProPhase Labs Unveils Project ZenQ-AI; Leveraging ProPhase Labs' AI Platform, Massive Genomics Database And Patented Esophageal Cancer Insights For Antibody Drug Conjugates Development
Leveraging ProPhase Labs' AI platform, massive genomics database and patented esophageal cancer insights for Antibody Drug Conjugates development. Garden City, NY, April 16, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH) ("ProPhase" or the "Company"), a biopharma, genomics, and diagnostics Company, today announced an innovative step forward in cancer treatment research with the introduction of Project ZenQ-AI. This project employs the Company's state-of-the-art AI platform which was meticulously developed with leading AI technology platforms and systems. The Company is harnessing its extensive genomic database—built over the last six years from whole genome sequencing tests (WGS)
4/16/24 8:15:30 AM ET
$PRPH
Biotechnology: Pharmaceutical Preparations
Health Care

ProPhase Labs Q1 2024 GAAP EPS $(0.07) Beats $(0.18) Estimate, Sales $3.634M Miss $9.860M Estimate

Chat with this insight

Recent Analyst Ratings for $PRPH

$PRPH Leadership Updates

Live Leadership Updates

ProPhase Labs Unveils Project ZenQ-AI

Sidus Space Appoints Bill White as Chief Financial Officer

Nebula Genomics Strengthens Advisory Board with Appointment of Russ Altman, M.D., Ph.D.

$PRPH Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

HC Wainwright & Co. reiterated coverage on ProPhase Labs with a new price target

HC Wainwright & Co. initiated coverage on ProPhase Labs with a new price target

ProPhase downgraded by Dawson James

$PRPH Financials

Live finance-specific insights

$PRPH Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$PRPH Press Releases

Fastest customizable press release news feed in the world

ProPhase Labs Announces Financial Results for the Three Months Ended September 30, 2024

ProPhase Labs Inc. to Present Third Quarter 2024 Financial Results on November 13, 2024

ProPhase Labs Announces Financial Results for the Three Months Ended June 30, 2024

SEC Form 4 filed by Karkus Ted William (Amendment)

SEC Form 4 filed by Latkin Jed

SEC Form 3 filed by new insider Latkin Jed

Impact BioMedical Inc. Issues Shareholder Letter Highlighting Recent Achievements and Strategic Vision

Diamond Equity Research Releases Update Note on ProPhase Labs Inc. (NASDAQ: PRPH)

ProPhase Labs Announces Financial Results for the Three Months Ended September 30, 2024

$PRPH SEC Filings

SEC Form EFFECT filed by ProPhase Labs Inc.

SEC Form 10-Q filed by ProPhase Labs Inc.

SEC Form NT 10-Q filed by ProPhase Labs Inc.

$PRPH Market Insights

Live Market Insights

ProPhase Labs Announces Update On Pharmaloz Manufacturing Progress; Says PMI's 12-Month Forward Looking Revenue Run Rate With One Production Line Will Be ~$14M-16M And ~$5M In Pre-Tax Net Profits

ProPhase Labs Q1 2024 GAAP EPS $(0.07) Beats $(0.18) Estimate, Sales $3.634M Miss $9.860M Estimate

ProPhase Labs Unveils Project ZenQ-AI; Leveraging ProPhase Labs' AI Platform, Massive Genomics Database And Patented Esophageal Cancer Insights For Antibody Drug Conjugates Development

$PRPH Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13D/A filed by ProPhase Labs Inc. (Amendment)

SEC Form SC 13D/A filed by ProPhase Labs Inc. (Amendment)

SEC Form SC 13D/A filed by ProPhase Labs Inc. (Amendment)

Recent Analyst Ratings for
$PRPH

$PRPH
Leadership Updates

$PRPH
Analyst Ratings

$PRPH
Financials

$PRPH
Insider Trading

$PRPH
Press Releases

$PRPH
SEC Filings

$PRPH
Market Insights

$PRPH
Large Ownership Changes